Algorithms of diagnosis and options of hepatocellular carcinoma therapy

  • A. Forner
  • J. M. Llovet
Conference paper
Part of the Falk Symposium book series (FASS, volume 160)

Abstract

In the past two decades hepatocellular carcinoma (HCC) has experienced a progressive increase in its incidence, at present constituting the sixth most common cancer worldwide, the third cause of cancer-related mortality1 and the main cause of death among cirrhotic patients.2 These facts are mostly due to the long-term impact of chronic hepatitis C virus (HCV) infection, along with the increase in early detection.3

Keywords

Hepatitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–10.PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.PubMedCrossRefGoogle Scholar
  7. 7.
    Villanueva A, Newell P, Chiang DY, Friedman SF, Llovet JM. Genomics and signaling pathways In hepatocellular carcinoma. Semin Liver Dis. 2007;27:55–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Llovet JM, Chen Y, Wurmbach E et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758–67.PubMedCrossRefGoogle Scholar
  9. 9.
    Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis. 2005;25:171–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedGoogle Scholar
  11. 11.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology. 2004;127(Suppl. 1):S51–5.CrossRefGoogle Scholar
  13. 13.
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.PubMedCrossRefGoogle Scholar
  14. 14.
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Imamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Sala M, Fuster J, Llovet JM et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transplant. 2004;10:1294–300.CrossRefGoogle Scholar
  17. 17.
    Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology. 2001;33:1073–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Llovet JM, Mas X, Aponte JJ et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002;50:123–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10:8421–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Beaugrand M, N’Kontchou G, Seror O, Ganne N, Trinchet JC. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis. 2005;25:201–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Lencioni R, Cioni D, Crocetti L et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–61.PubMedGoogle Scholar
  27. 27.
    Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Huang GT, Lee PH, Tsang YM et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg. 2005;242:36–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl. 1):S179–88.CrossRefGoogle Scholar
  31. 31.
    Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Varela M, Real M, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads. Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Kulik LM, Carr B, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma presenting with or without portal vein thrombosis. Hepatology. 2008;47:71–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.PubMedCrossRefGoogle Scholar
  37. 37.
    Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005;25:212–25.PubMedCrossRefGoogle Scholar
  38. 38.
    Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–300.PubMedCrossRefGoogle Scholar
  40. 40.
    Llovet J, Ricci S, Mazzaferro V et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2007;25(18S): LBA1.Google Scholar
  41. 41.
    Philip P, Mahoney M, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657–63.PubMedCrossRefGoogle Scholar
  42. 42.
    O’Dwyer P, Giantonio B, Levy D, Kauh J, Fitzgerald D, Benson A III. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group’s Study E1203. J Clin Oncol. 2006;24(Suppl.):4143.Google Scholar
  43. 43.
    Schwartz J, Schwartz M, Lehrer D et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol. 2006;24(Suppl.):4144.Google Scholar
  44. 44.
    Zhu A, Sahani D, di Tomaso E et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2007;25(Suppl.):4637.Google Scholar

Copyright information

© Springer and Falk Foundation e.V. 2008

Authors and Affiliations

  • A. Forner
    • 1
  • J. M. Llovet
  1. 1.Barcelona Clinic Liver Cancer (BCLC) Group Liver Unit Hospital Clinic IDIBAPS CIBERehdUniversity BarcelonaBarcelonaSpain

Personalised recommendations